The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation

This publication has 26 references indexed in Scilit:

• Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens
  Climacteric, 2004
• Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis
  Climacteric, 2004
• Additive effect of drospirenone/17-β-estradiol in hypertensive postmenopausal women receiving enalapril1
  American Journal of Hypertension, 2002
• Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use
  Contraception, 2002
• Third generation oral contraceptives and risk of venous thrombosis: meta-analysis
  BMJ, 2001
• Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
  Contraception, 2000
• Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study
  BMJ, 1996
• Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
  The Lancet, 1995
• Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
  The Lancet, 1995
• Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
  The Lancet, 1995